Molecure S.A. (MOC) - Total Assets
Based on the latest financial reports, Molecure S.A. (MOC) holds total assets worth zł107.45 Million PLN (≈ $29.57 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Molecure S.A. - Total Assets Trend (2014–2024)
This chart illustrates how Molecure S.A.'s total assets have evolved over time, based on quarterly financial data. Also see MOC market cap overview for the company's overall valuation and market capitalisation.
Molecure S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Molecure S.A.'s total assets of zł107.45 Million consist of 44.2% current assets and 55.8% non-current assets. Review total liabilities of Molecure S.A. to assess the company's total debt and financial obligations.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 16.0% |
| Accounts Receivable | zł30.32 Million | 26.7% |
| Inventory | zł0.00 | 0.0% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł53.97 Million | 47.5% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Molecure S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Molecure S.A. stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Molecure S.A.'s current assets represent 44.2% of total assets in 2024, a decrease from 59.3% in 2014.
- Cash Position: Cash and equivalents constituted 16.0% of total assets in 2024, down from 50.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 40.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 47.5% of total assets.
Molecure S.A. Competitors by Total Assets
Key competitors of Molecure S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
Molecure S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.28 | 5.79 | 8.39 |
| Quick Ratio | 10.28 | 5.79 | 8.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł37.52 Million | zł45.09 Million | zł27.48 Million |
Molecure S.A. - Advanced Valuation Insights
This section examines the relationship between Molecure S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.76 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | zł113.72 Million |
| Market Capitalization | $45.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Molecure S.A.'s assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Molecure S.A.'s assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Molecure S.A. (2014–2024)
The table below shows the annual total assets of Molecure S.A. from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł113.72 Million ≈ $31.30 Million |
+1.29% |
| 2023-12-31 | zł112.27 Million ≈ $30.90 Million |
-18.68% |
| 2022-12-31 | zł138.06 Million ≈ $38.00 Million |
-8.93% |
| 2021-12-31 | zł151.59 Million ≈ $41.72 Million |
-1.24% |
| 2020-12-31 | zł153.50 Million ≈ $42.25 Million |
+79.14% |
| 2019-12-31 | zł85.69 Million ≈ $23.58 Million |
-0.38% |
| 2018-12-31 | zł86.02 Million ≈ $23.67 Million |
+148.82% |
| 2017-12-31 | zł34.57 Million ≈ $9.51 Million |
+122.81% |
| 2016-12-31 | zł15.52 Million ≈ $4.27 Million |
-6.09% |
| 2015-12-31 | zł16.52 Million ≈ $4.55 Million |
+263.60% |
| 2014-12-31 | zł4.54 Million ≈ $1.25 Million |
-- |
About Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis a… Read more